You are here

odalasvir

J&J scraps a multibillion-dollar hepatitis C program after rivals divvy up the market

Endpoints

Mon, 09/11/17 - 09:40 am

J&J advances through PhII with a promising hep C triple and 100% cure rate

Endpoints

Fri, 09/9/16 - 10:21 am

clinical trials

8 Major FDA Decisions and Trial Results to Watch for in September

24/7 Wall St

Sat, 09/3/16 - 12:17 pm

Array Biopharma

Mast Therapeutics

Threshold Pharmaceuticals

3 Biotechs Expecting Market-Moving Trial Results Soon

Motley Fool

Mon, 06/6/16 - 11:07 am

Johnson & Johnson And Achillion Pharmaceuticals May Offer Fastest 100% Cure With Their HCV Combo

Bidness, ETC

Fri, 09/18/15 - 10:56 am

Gilead Sciences